search
Back to results

Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response

Primary Purpose

Infertility, Female, Ovarian Stimulation, In Vitro Fertilisation

Status
Unknown status
Phase
Phase 4
Locations
Russian Federation
Study Type
Interventional
Intervention
Pergoveris
Clomiphene
Sponsored by
Nova Clinic, Russia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility, Female focused on measuring Suboptimal ovarian response, Ovarian Stimulation, Infertility, Female, In Vitro Fertilisation

Eligibility Criteria

37 Years - 42 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. 37 - 42 years of age
  2. BMI 18-30 kg\m2
  3. Suboptimal ovarian responders with normal ovarian reserve: the number of antral follicles greater than 5 and AMH greater than 1.2 ng / ml, resulting in 4-9 oocytes after a standard ovarian stimulation, according Poseidon classification - group 2b
  4. Informed consent

Exclusion Criteria:

  1. Medical contraindications for IVF
  2. Basal follicle stimulating hormone (FSH) more 15 IU/L
  3. Severe mail factor

Sites / Locations

  • Irina ZorinaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

DUOSTIM group

Modified Shanghai Protocol group

Arm Description

Pergoveris 150 -300 IU start from day 2 of the cycle up to the day of trigger, GnRH antagonist 0,25 mg start from day 7-8 of the cycle up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, stop period for 5 days, after stop period start Pergoveris 150 - 300 IU start up to the day of trigger, GnRH antagonist 0,25 mg start from day 6 of ovarian stimulation up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.

Clomiphene 50 mg start from day 2-3 of the cycle up to the day of trigger, Pergoveris 150 - 300 IU - 6,8, 10 days of the cycle, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, after stop period for 2-3 days start Pergoveris 150 - 300 IU up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.

Outcomes

Primary Outcome Measures

Total number of retrieved oocytes per cycle
evaluation the total number of retrieved oocytes after double ovarian stimulation in one cycle

Secondary Outcome Measures

total number of blastocyst per cycle
evaluation the total number of blastocyst after double ovarian stimulation in one cycle
Time until embryo transfer
period from start double ovarian stimulation until embryo transfer
number of cycles need to treat
number of cycles with double ovarian stimulation required to obtain 3-5 blastocyst
pregnancy rate
pregnancy rate after embryo transfer of thawed blastocyst
the birth rate
the birth rate after embryo transfer

Full Information

First Posted
December 19, 2017
Last Updated
January 14, 2018
Sponsor
Nova Clinic, Russia
search

1. Study Identification

Unique Protocol Identification Number
NCT03400722
Brief Title
Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response
Official Title
Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response in Assisted Reproductive Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Unknown status
Study Start Date
December 1, 2017 (Actual)
Primary Completion Date
August 1, 2018 (Anticipated)
Study Completion Date
May 1, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nova Clinic, Russia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients with infertility of the older age group of 37-42 years - a large cohort of patients of reproductive medicine. Two possible causes reduce their probability of pregnancy - an increasing age and a decrease of the ovarian reserve. In these conditions, the early receipt of embryos for future transfer can serve as a correct strategy for treating infertility in this category of patients. According to statistical data, patients of the 37-42-year-old age group need 3-5 blastocysts, out of them 1-2 euploid to achieve pregnancy. The POSEIDON group of researchers identified a group of 2b patients with a suboptimal response to the induction of superovulation in IVF programs - patients older than 35 years with a normal ovarian reserve (the number of antral follicles greater than 5 and Anti-Müllerian hormone (AMH) greater than 1.2 ng / ml), resulting in 4-9 oocytes after a standard ovarian stimulation. In this situation standard stimulation protocols can stretch the process of obtaining embryos indefinitely, during which the patient will move to another age category with a decrease in the likelihood of pregnancy. Thus, these patients are shown the fastest reception of oocytes and the accumulation of embryos, which can be done using double ovarian stimulation in the same menstrual cycle. The aim of the study is to compare the different schemes of double stimulation in patients with infertility of the older age group of 37-42 years with the preceding suboptimal response. Group 1 - patients of the DUOSTIM group. Group 2 - Patients of the Shanghai Protocol. The investigated parameters - primary outcome measures: total number of retrieved oocytes per cycle, secondary outcome measures: total number of blastocyst per cycle, number of cycles with double ovarian stimulation required to obtain 3-5 blastocyst, time until embryo transfer, pregnancy rate and birth rate This is a prospective randomized non-blinded clinical study.
Detailed Description
The aim of the study is to compare the different schemes of double stimulation in patients with infertility of the older age group of 37-42 years with the preceding suboptimal response. Materials and methods. Patients with preserved ovarian reserve of 37-42 years old, who had the history of standard stimulation in IVF programs, which produce less 4-7 oocytes. Patients will be randomised in two groups. Group 1 - patients of the double ovarian stimulation in the same cycle with recombinant gonadotropin (DUOSTIM group). Group 2 - patients of the double ovarian stimulation in the same cycle with clomifen and recombinant gonadotropin (modified Shanghai Protocol). The stimulation protocol in the Group 1 - Follitropin and Lutropin Alfa (Pergoveris) 150 -300 IU start from day 2 of the cycle up to the day of trigger, gonadotropin-releasing hormone (GnRH) antagonist 0,25 mg start from day 7-8 of the cycle up to the day of trigger, final trigger of ovarian stimulation - gonadotropin-releasing hormone agonist (GnRH-a) 0,2 mg, oocyte retrieval 35 hours after trigger, stop period for 5 days, after stop period start Pergoveris 150 - 300 IU start up to the day of trigger, GnRH antagonist 0,25 mg start from day 6 of ovarian stimulation up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by invitro insemination (IVI) or intracytoplasmic sperm injection (ICSI), the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed. The cycles of double ovarian stimulation will be performed until the patient will have not less than 3-5 blastocysts. Then the embryo accumulation process will be completed and the unfrozen embryos transferred in the hormonal replacement cycle or natural ovulatory cycle. The stimulation protocol in the Group 2 - Clomiphene 50 mg start from day 2-3 of the cycle up to the day of trigger, Pergoveris 150 IU - 6,8, 10 days of the cycle, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, after stop period for 2-3 days start Pergoveris 150 - 300 IU up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed. The cycles of double ovarian stimulation will be performed until the patient will have not less than 3-5 blastocysts. Then the embryo accumulation process will be completed and the unfrozen embryos transferred in the hormonal replacement cycle or natural ovulatory cycle.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility, Female, Ovarian Stimulation, In Vitro Fertilisation
Keywords
Suboptimal ovarian response, Ovarian Stimulation, Infertility, Female, In Vitro Fertilisation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
DUOSTIM group
Arm Type
Experimental
Arm Description
Pergoveris 150 -300 IU start from day 2 of the cycle up to the day of trigger, GnRH antagonist 0,25 mg start from day 7-8 of the cycle up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, stop period for 5 days, after stop period start Pergoveris 150 - 300 IU start up to the day of trigger, GnRH antagonist 0,25 mg start from day 6 of ovarian stimulation up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
Arm Title
Modified Shanghai Protocol group
Arm Type
Experimental
Arm Description
Clomiphene 50 mg start from day 2-3 of the cycle up to the day of trigger, Pergoveris 150 - 300 IU - 6,8, 10 days of the cycle, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, after stop period for 2-3 days start Pergoveris 150 - 300 IU up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
Intervention Type
Drug
Intervention Name(s)
Pergoveris
Other Intervention Name(s)
antagonist of gonadotropin releasing hormone, agonist of gonadotropin releasing hormone
Intervention Description
Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
Intervention Type
Drug
Intervention Name(s)
Clomiphene
Other Intervention Name(s)
Pergoveris, agonist of gonadotropin releasing hormone
Intervention Description
Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
Primary Outcome Measure Information:
Title
Total number of retrieved oocytes per cycle
Description
evaluation the total number of retrieved oocytes after double ovarian stimulation in one cycle
Time Frame
up to 9 months
Secondary Outcome Measure Information:
Title
total number of blastocyst per cycle
Description
evaluation the total number of blastocyst after double ovarian stimulation in one cycle
Time Frame
up to 9 months
Title
Time until embryo transfer
Description
period from start double ovarian stimulation until embryo transfer
Time Frame
up to 9 months
Title
number of cycles need to treat
Description
number of cycles with double ovarian stimulation required to obtain 3-5 blastocyst
Time Frame
up to 9 months
Title
pregnancy rate
Description
pregnancy rate after embryo transfer of thawed blastocyst
Time Frame
up to 9 months
Title
the birth rate
Description
the birth rate after embryo transfer
Time Frame
up to 18 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
37 Years
Maximum Age & Unit of Time
42 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 37 - 42 years of age BMI 18-30 kg\m2 Suboptimal ovarian responders with normal ovarian reserve: the number of antral follicles greater than 5 and AMH greater than 1.2 ng / ml, resulting in 4-9 oocytes after a standard ovarian stimulation, according Poseidon classification - group 2b Informed consent Exclusion Criteria: Medical contraindications for IVF Basal follicle stimulating hormone (FSH) more 15 IU/L Severe mail factor
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Irina Zorina, M.D.,Ph.D.
Phone
+79263407621
Email
irinazorina@yandex.ru
First Name & Middle Initial & Last Name or Official Title & Degree
Irina Zorina, M.D.,Ph.D.
Phone
+74952211188
Email
i.zorina@nova-clinic.ru
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Konstantin Dancheev
Organizational Affiliation
MEDINSERVIS LLC NOVA CLINIC
Official's Role
Study Director
Facility Information:
Facility Name
Irina Zorina
City
Moscow
ZIP/Postal Code
119048
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Irina Zorina, M.D.,Ph.D
Phone
+74992210688
Email
irinazorina@yandex.ru
First Name & Middle Initial & Last Name & Degree
Yulia Tsoraeva, M.D.
Phone
+74992210688
Email
tsoraevadz@mail.ru

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response

We'll reach out to this number within 24 hrs